Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study
Michelle C Janelsins, Charles E Heckler, Luke J Peppone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2025
Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update
Ko Un Park, Mark R Somerfield, Nirupama Anne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 2021
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222
Halle C F Moore, William E Barlow, George Somlo, et al.
Clinical Breast Cancer
|
October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5
John W Smith, Marc E Buyse, Priya Rastogi, et al.
NPJ Breast Cancer
|
March 18, 2026
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer
Alan Su, Erin C Hong, Nicole Moxon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer
David B Page, Joanna Pucilowska, Katherine G Sanchez, et al.
JAMA Surgery
|
July 1, 2026
Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial
Irene L Wapnir, Reena S Cecchini, James J Dignam, et al.
Clinical Breast Cancer
|
May 8, 2025
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium
Komal Jhaveri, Carey K Anders, Aditya Bardia, et al.
The New England Journal of Medicine
|
December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
The New England Journal of Medicine
|
January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
Charles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study
Michelle C Janelsins, Charles E Heckler, Luke J Peppone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2025
Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update
Ko Un Park, Mark R Somerfield, Nirupama Anne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 2021
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222
Halle C F Moore, William E Barlow, George Somlo, et al.
Clinical Breast Cancer
|
October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5
John W Smith, Marc E Buyse, Priya Rastogi, et al.
NPJ Breast Cancer
|
March 18, 2026
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer
Alan Su, Erin C Hong, Nicole Moxon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer
David B Page, Joanna Pucilowska, Katherine G Sanchez, et al.
JAMA Surgery
|
July 1, 2026
Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial
Irene L Wapnir, Reena S Cecchini, James J Dignam, et al.
Clinical Breast Cancer
|
May 8, 2025
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium
Komal Jhaveri, Carey K Anders, Aditya Bardia, et al.
The New England Journal of Medicine
|
December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
The New England Journal of Medicine
|
January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
Charles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.
Page
of 3